Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1032650-41-1 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1032650-41-1 ]

CAS No. :	1032650-41-1
Formula :	C₆H₃BrClN₃
M.W :	232.47
SMILES Code :	ClC1=C(NC=C2Br)C2=NC=N1
MDL No. :	MFCD11518977
InChI Key :	MSHYYIJDYMVONW-UHFFFAOYSA-N
Pubchem ID :	52987660

Safety of [ 1032650-41-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 1032650-41-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	9
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	46.6
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	41.57 ?2

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.67
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.07
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.37
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.13
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.89
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.03

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.19
Solubility	0.15 mg/ml ; 0.000644 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.57
Solubility	0.623 mg/ml ; 0.00268 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.01
Solubility	0.0225 mg/ml ; 0.0000968 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.25 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.83

Application In Synthesis of [ 1032650-41-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1032650-41-1 ]

[ 1032650-41-1 ] Synthesis Path-Downstream 1~31

1
[ 917494-85-0 ]
[ 1032650-41-1 ]
[ 1032648-89-7 ]

Yield	Reaction Conditions	Operation in experiment
32%		To a chilled (-780C) solution of 7-bromo-4-chloro-5H-pyrrolo[3,2-?]pyrimidine (80 mg, 0.34 mmol, 1 equiv.) in 5 mL of TetaF was added tert-BwLi (1.7 M in pentane, 0.43 mL, 0.73 mmol, 2.1 equiv.) dropwise. After 5 minutes, a chilled (-780C) solution of 2,2,2-trifluoro-l-[l-(4- fluorophenyl)-lH-indazol-5-yl]ethanone (106 mg, 0.34 mmol, 1 equiv.) in 1 mL of TetaF was added in one portion. After 15 minutes, the reaction was quenched with 15 mL of water, warmed to room temperature, diluted with 100 mL of saturated aqueous ammonium chloride, and then extracted with EtOAc. The combined organic layers were dried, filtered, and concentrated in vacuo. The residue was dissolved in DMF and purified by reverse phase etaPLC (5-95% Ceta3Cnu/water +0.1% TFA). The major fractions collected were made basic with saturated NaHCO3 and the CH3CN was concentrated in vacuo. The aqueous was extracted with <n="156"/>EtOAc and washed with brine. The organic layers were dried, filtered, and concentrated in vacuo to provide 52 mg (32%) of the title compound as a white solid. MS m/z 462.56 (MH+).

References: [1]Patent: WO2008/70507,2008,A2 .Location in patent: Page/Page column 153-154.

2
[ 93587-23-6 ]
[ 1032650-41-1 ]

Yield	Reaction Conditions	Operation in experiment
93%		A mixture of 7-bromo-3,5-dihydropyrrolo[3,2-?]pyrimidin-4-one (100 mg, 0.5 mmol) and 6 mL of POCI3 under argon was warmed at 115C. After 3 hours, the mixture was cooled to room temperature and poured over 300 mL of ice, stirred, made basic with potassium carbonate and extracted with EtOAc. The combined organic layers were dried, filtered, and concentrated in vacuo to provide 101 mg (93%) of the desired 7-bromo-4-chloro-5H-pyrrolo[3,2- djpyrimidine as beige solid which was used without further purification.
90%	With trichlorophosphate; for 2.0h;Inert atmosphere; Reflux;	Under argon atmosphere, a solution of 7-Bromo-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one (500 mg, 2.33 mmol) in phosphorus(V) oxychoride (6 rriL) was refluxed for 2 hours. The reaction mixture was then cooled to room temperature, concentrated and the residue was diluted with ethyl acetate. The organic layer was washed with a solution of sodium bicarbonate, brine, dried over sodium sulfate, filtered and evaporated under reduced pressure to afford compound (66a) as a pale solid (490 mg, 2.10 mmol, 90%) without further purification. lH NMR (400 MHz, DMSO-i delta 8.24 (d, J = 3.0 Hz, 1H), 8.72 (s, 1H), 12.95 (bs, 1H). MS m/z ([M+H]+) 232/234
35%	With trichlorophosphate; at 115℃; for 3.0h;	Intermediate 98 (1.30 g, 6.07 mmol) was suspended in POCI3 (60 mL) and heated at 115 C for 3 h. The reaction mixture was cooled to r.t. and poured cautiously onto ice (300 mL). The reaction mixture was basified with K2CO3 and extracted with EtOAc (3 x 200 mL). The combined organic fractions were dried (MgS04) and concentrated in vacuo to give the title compound as a beige solid (490 mg, 35%). LCMS (ES+): 231.9, 233.9, 235.9 (M+H)+.

35%

With trichlorophosphate; at 115℃; for 3.0h;

Intermediate 98 (1.30 g, 6.07 mmol) was suspended in POCl3 (60 mL) and heated at 115 C. for 3 h. The reaction mixture was cooled to r.t. and poured cautiously onto ice (300 mL). The reaction mixture was basified with K2CO3 and extracted with EtOAc (3*200 mL). The combined organic fractions were dried (MgSO4) and concentrated in vacuo to give the title compound as a beige solid (490 mg, 35%). LCMS (ES+): 231.9, 233.9, 235.9 (M+H)+.

References: [1]Patent: WO2008/70507,2008,A2 .Location in patent: Page/Page column 153.
[2]Patent: WO2015/128334,2015,A1 .Location in patent: Page/Page column 90.
[3]Patent: WO2011/113798,2011,A2 .Location in patent: Page/Page column 59-60.
[4]Patent: US2013/102587,2013,A1 .Location in patent: Paragraph 0273; 0274.

3
[ 1032650-41-1 ]
[ 217300-17-9 ]
[ 1255939-59-3 ]

References: [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 7274 - 7282.

4
[ 1032650-41-1 ]
[ 74-88-4 ]
[ 1255939-58-2 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydride; In tetrahydrofuran; oil; for 18h;	Step 1 : To Compound 13-1 (0.30g, 1.3mmol) and CH3I (0.12mL, 1.9mmol ) in THF (5mL) was added NaH (60% in oil, 0.078g, 1 ,9mmol). The mixture was stirred 18h and concentrated.
		romo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine To <strong>[1032650-41-1]7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine</strong> (147 mg), N,N- dimethylformamide (10 mL) was added, and NaH (36 mg) was further added thereto, followed by stirring for 30 min. Subsequently, methyl iodide was added thereto, and the reaction mixture was heated to 50C and stirred for 2 hours. After completion of the reaction, the reaction mixture was mixed with ethyl acetate and washed with water. The washed mixture was dried over anhydrous sodium sulfate, and filtered and distilled under reduced pressure to obtain the title compound. 'H NMR (300 MHz, DMSO- 6): delta 8.68(s, 1H), 8.22(s, 1H), 4.11(s, 3H).
		To <strong>[1032650-41-1]7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine</strong> (147 mg), N,N-dimethylformamide (10 mL) was added, and NaH (36 mg) was further added thereto, followed by stirring for 30 min. Subsequently, methyl iodide was added thereto, and the reaction mixture was heated to 50 C. and stirred for 2 hours. After completion of the reaction, the reaction mixture was mixed with ethyl acetate and washed with water. The washed mixture was dried over anhydrous sodium sulfate, and filtered and distilled under reduced pressure to obtain the title compound. [0214] 1H NMR (300 MHz, DMSO-d6): delta 8.68 (s, 1H), 8.22 (s, 1H), 4.11 (s, 3H).

		Step 4: Preparation of 7-bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine N,N-dimethylformamide (10 mL) and NaH (36 mg) were added to <strong>[1032650-41-1]7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine</strong> (147 mg), followed by stirring for 30 mins. Subsequently, methyl iodide was added thereto, and the mixture was heated under stirring at 50C for 2 hrs. Upon completion of the reaction, ethyl acetate was added thereto, and the mixture was washed with water. The resulting compound was dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure to obtain the title compound. 1H NMR (300 MHz, DMSO-d6): delta 8.68(s, 1H), 8.22(s, 1H), 4.11 (s, 3H).
		Step 4: Preparation of 7-bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine N,N-dimethylformamide (10 mL) and NaH (36 mg) were added to <strong>[1032650-41-1]7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine</strong> (147 mg), followed by stirring for 30 mins. Subsequently, methyl iodide was added thereto, and the mixture was heated under stirring at 50 C. for 2 hrs. Upon completion of the reaction, ethyl acetate was added thereto, and the mixture was washed with water. The resulting compound was dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure to obtain the title compound. 1H NMR (300 MHz, DMSO-d6): delta 8.68 (s, 1H), 8.22 (s, 1H), 4.11 (s, 3H).

References: [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 7274 - 7282.
[2]Patent: WO2011/159657,2011,A1 .Location in patent: Page/Page column 60.
[3]Patent: WO2012/93809,2012,A2 .Location in patent: Page/Page column 30.
[4]Patent: US2013/274268,2013,A1 .Location in patent: Paragraph 0212-0214.
[5]Patent: EP2738174,2014,A2 .Location in patent: Paragraph 0045; 0052; 0053.
[6]Patent: US2014/163226,2014,A1 .Location in patent: Paragraph 0137-0139.

5
[ 84905-80-6 ]
[ 1032650-41-1 ]

Yield	Reaction Conditions	Operation in experiment
	With N-Bromosuccinimide; In tetrahydrofuran; for 1h;	Step 4-3) 7-bromo-4-chloro-5H-pyrrolo["3,2-dlpyrimidine To 4-chloro-5H-pyrrolo[3,2-i/]pyrimidine (100 mg), tetrahydrofuran (5 mL) was added, and N-bromosuccinimide (116 mg) was further added thereto, followed by stirring for 1 hour. After completion of the reaction, the reaction mixture was mixed with ethyl acetate and washed with water. The washed mixture was dried over anhydrous sodium sulfate, and filtered and distilled under reduced pressure to obtain the title compound. 'H NMR (300 MHz, DMSO-i?): delta 12.95 (s, 1 H), 8.71 (s, 1 H), 8.24 (d, 1 H).
	With N-Bromosuccinimide; In tetrahydrofuran; for 1h;	To 4-chloro-5H-pyrrolo[3,2-d]pyrimidine (100 mg), tetrahydrofuran (5 mL) was added, and N-bromosuccinimide (116 mg) was further added thereto, followed by stirring for 1 hour. After completion of the reaction, the reaction mixture was mixed with ethyl acetate and washed with water. The washed mixture was dried over anhydrous sodium sulfate, and filtered and distilled under reduced pressure to obtain the title compound. [0211] 1H NMR (300 MHz, DMSO-d6): delta 12.95 (s, 1H), 8.71 (s, 1H), 8.24 (d, 1H)
	With N-Bromosuccinimide; In tetrahydrofuran; for 1h;	Step 3: Preparation of 7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine Tetrahydrofuran (5 mL) and N-bromosuccinimide (116 mg) were added to 4-chloro-5H-pyrrolo[3,2-d]pyrimidine (100 mg). The mixture was stirred for 1 hr and, upon completion of the reaction, ethyl acetate was added thereto, and washed with water. The mixture was dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure to obtain the title compound. 1H NMR (300 MHz, DMSO-d6): delta 12.95 (s, 1 H), 8.71 (s, 1 H), 8.24 (d, 1 H)

With N-Bromosuccinimide; In tetrahydrofuran; for 1h;

Step 3: Preparation of 7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine Tetrahydrofuran (5 mL) and N-bromosuccinimide (116 mg) were added to 4-chloro-5H-pyrrolo[3,2-d]pyrimidine (100 mg). The mixture was stirred for 1 hr and, upon completion of the reaction, ethyl acetate was added thereto, and washed with water. The mixture was dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure to obtain the title compound. 1H NMR (300 MHz, DMSO-d6): delta 12.95 (s, 1H), 8.71 (s, 1H), 8.24 (d, 1H)

References: [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 7274 - 7282.
[2]Patent: WO2012/93809,2012,A2 .Location in patent: Page/Page column 29-30.
[3]Patent: US2013/274268,2013,A1 .Location in patent: Paragraph 0209-0211.
[4]Patent: EP2738174,2014,A2 .Location in patent: Paragraph 0045; 0050; 0051.
[5]Patent: US2014/163226,2014,A1 .Location in patent: Paragraph 0134-0136.

6
[ 29943-42-8 ]
[ 1032650-41-1 ]
[ 1334713-76-6 ]

Yield	Reaction Conditions	Operation in experiment
		Intermediate 99 (500 mg, 2.15 mmol) was dissolved in THF (30 mL) and cooled to -78 C. tBuLi (3.39 mL, 1.9 M in pentane, 6.45 mmol) was added drop-wise and the reaction mixture was stirred at -78 C for 5 min. A solution of oxan-4-one (1.08 g, 10.8 mmol) in THF (10 mL) was added and the reaction mixture was stirred at -78 C for 30 min and then warmed to r.t.. The reaction mixture was quenched with water (5 mL) and concentrated in vacuo. The residue was purified by reverse phase column chromatography to give the crude title compound as a yellow solid (507 mg, 100%).LCMS (ES+): 236.0 (M+H)+.
		Intermediate 99 (500 mg, 2.15 mmol) was dissolved in THF (30 mL) and cooled to -78 C. tBuLi (3.39 mL, 1.9 M in pentane, 6.45 mmol) was added drop-wise and the reaction mixture was stirred at -78 C. for 5 min. A solution of oxan-4-one (1.08 g, 10.8 mmol) in THF (10 mL) was added and the reaction mixture was stirred at -78 C. for 30 min and then warmed to r.t. The reaction mixture was quenched with water (5 mL) and concentrated in vacuo. The residue was purified by reverse phase column chromatography to give the crude title compound as a yellow solid (507 mg, 100%). LCMS (ES+): 236.0 (M+H)+.

References: [1]Patent: WO2011/113798,2011,A2 .Location in patent: Page/Page column 60.
[2]Patent: US2013/102587,2013,A1 .Location in patent: Paragraph 0275; 0276.

7
[ 5655-01-6 ]
[ 1032650-41-1 ]

References: [1]Patent: WO2011/113798,2011,A2 .
[2]Patent: WO2012/93809,2012,A2 .
[3]Patent: US2013/274268,2013,A1 .
[4]Patent: EP2738174,2014,A2 .

8
3-amino-2-ethoxycarbonylpyrrole hydrochloride [ No CAS ]
[ 1032650-41-1 ]

References: [1]Patent: WO2011/113798,2011,A2 .
[2]Patent: US2013/102587,2013,A1 .

9
[ 1032650-41-1 ]
[ 1334713-77-7 ]

References: [1]Patent: WO2011/113798,2011,A2 .
[2]Patent: US2013/102587,2013,A1 .

10
[ 1032650-41-1 ]
[ 1334712-78-5 ]

References: [1]Patent: WO2011/113798,2011,A2 .
[2]Patent: US2013/102587,2013,A1 .

11
[ 1032650-41-1 ]
[ 24424-99-5 ]
[ 1352813-07-0 ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; In tetrahydrofuran; for 18h;	Example 13Step 1 : To Compound 13-1 (0.50g, 2.2mmol) in THF (15mL) were added di-t-butyl dicarbonate (0.56g, 2.6mmol) and 4-(dimethylamino)pyridine.(0.026g, 0.21mmol). The mixture was stirred 18h and concentrated to provide crude Compound 13-2.

References: [1]Patent: WO2011/159657,2011,A1 .Location in patent: Page/Page column 58.

12
[ 1032650-41-1 ]
[ 24424-99-5 ]
[ 1352813-08-1 ]

References: [1]Patent: WO2011/159657,2011,A1 .

13
[ 1032650-41-1 ]
[ 1352813-11-6 ]

References: [1]Patent: WO2011/159657,2011,A1 .

14
[ 779326-74-8 ]
[ 1032650-41-1 ]

References: [1]Patent: WO2012/93809,2012,A2 .
[2]Patent: US2013/274268,2013,A1 .
[3]Patent: EP2738174,2014,A2 .
[4]Patent: US2014/163226,2014,A1 .

15
[ 1032650-41-1 ]
[ 1384951-78-3 ]

References: [1]Patent: WO2012/93809,2012,A2 .
[2]Patent: US2013/274268,2013,A1 .

16
[ 1032650-41-1 ]
[ 1384950-68-8 ]

References: [1]Patent: WO2012/93809,2012,A2 .
[2]Patent: US2013/274268,2013,A1 .

17
[ 1032650-41-1 ]
[ 1384950-69-9 ]

References: [1]Patent: WO2012/93809,2012,A2 .
[2]Patent: US2013/274268,2013,A1 .

18
[ 1032650-41-1 ]
[ 1384951-79-4 ]

References: [1]Patent: WO2012/93809,2012,A2 .
[2]Patent: US2013/274268,2013,A1 .

19
[ 5655-01-6 ]
[ 1032650-41-1 ]

References: [1]Patent: US2013/102587,2013,A1 .

20
[ 1032650-41-1 ]
7-(1-cyclohexyl-1H-benzimidazol-5-yl)-N,N-dimethyl-4-oxo-3,4-dihydropyrrolo[3,2-d]pyrimidine-5-sulfonamide [ No CAS ]